2001


Nicola M. Shiels

Follow this and additional works at: https://scholar.smu.edu/lbra

Recommended Citation
Available at: https://scholar.smu.edu/lbra/vol7/iss3/8

This Comment is brought to you for free and open access by the Law Journals at SMU Scholar. It has been accepted for inclusion in Law and Business Review of the Americas by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu.

Nicola M. Shiels*

Table of Contents
I. Introduction
   A. Purpose of this Article
   B. NAFTA Provisions Regarding Intellectual Property
   C. Background on Biotechnology
   D. Transgenic Technology
   E. Movement to Procure Patent Protection for Living Organisms
   F. Controversy over Patentability of Animals
      1. Animal Patents in the United States
         a. The Three Patents Granted
         b. Controversy Over the Three Patents
         c. Current State of Patentability of Animals
      2. Animal Patents in Europe
         a. Rejection of Animal Patent
         b. Approval of Animal Patent
         c. Morality
         d. Public Policy Considerations
      3. Canada's Decision to Permit an Animal Patent
      4. International Law
   G. The "Harvard Mouse"
II. U.S. Case Law on Patentability of Living Organisms
III. Canadian Patent Protection Generally
   A. Statutory Protection
   B. Case Law on Patentability of Animals
IV. Canada's Approach Becoming More Like the United States

* J.D. Candidate, May 2002, Dedman School of Law at Southern Methodist University, Dallas, Texas. This article is an adaptation from a comment presented by Ms. Shiels as a member of the International Law Review Association of SMU (ILRA). As a member of ILRA, Ms. Shiels served as both a Staff Editor and Articles Editor.
V. Canada's Reaction to the Federal Appeals Court Decision

VI. Policy Reasons for the Uses of Transgenic Animals
   A. Reasons Against Patentability of Transgenic Animals
   B. Reasons For Patentability of Transgenic Animals
   C. International Considerations

VII. Conclusion

I. Introduction
   A. Purpose of this Article

   On August 3, 2000, Canada permitted a patent on the infamous “Harvard mouse.” The issue has been in the Canadian courts for about fifteen years, and even now the government has appealed the case to the Supreme Court of Canada. Canada has typically been reluctant to issue patents on “living organisms,” but as this article will demonstrate, Canada is slowly following the steps of other major countries around the world. This article questions whether Canada’s latest decision in the “Harvard mouse” case makes the provision about biological processes for the production of plants or animals in the NAFTA superfluous.

   B. NAFTA Provisions Regarding Intellectual Property

   Two international agreements dealing with the protection of plants and animals are the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), a part of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT), and the North American Free Trade Agreement (NAFTA). The TRIPS was the first international agreement to be passed. NAFTA came a little later and essentially adopted the same language as the TRIPS with regard to intellectual property rights on biological processes. These two agreements represent major accomplishments in efforts to harmonize patent laws throughout the world.

   NAFTA provides that the United States, Canada, and Mexico may exclude from patentability: “(a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals; (b) plants and animals other than microorganisms; and (c) essentially biological processes for the production of plants or animals, other than non-biological and microbiological processes for such production.” This language, which was modeled after article 27 of TRIPS, contains almost identical language regarding the exclusion of plants from patentable subject matter.

---

1. See General Agreement on Tariffs and Trade: Multilateral Trade Negotiations Final Act Embodying the Results of the Uruguay Round of Trade Negotiations, Apr. 15, 1994, 33 I.L.M. [hereinafter TRIPS].
3. Id.
4. See TRIPS, supra note 1, at 1208.
NAFTA does permit the member countries to patent products of nature. However, a member country may make exceptions "to protect human, animal or plant life or health or to avoid serious prejudice to nature or the environment." In addition, a member country can block the patenting of multi-cellular plants and animals, but it must allow the patenting of microorganisms and microbiological processes. Furthermore, Canada, Mexico, and the United States must extend reciprocal patent rights on "pharmaceutical or agricultural chemicals," including natural microbiological products and processes. Reciprocity demands uniform, least common denominator enforcement of intellectual property rights.

Since the passage of NAFTA, there has been concern that the permitted exclusions in NAFTA might allow large areas of technology to be declared unpatentable. People have argued that because NAFTA may exclude patentability on the basis of public order or morality, commercial interests are subject to the present or future whim of the general public. It has been argued that because these exceptions allow Canada and Mexico to exclude transgenic plants and animals from patentable subject matter, it diminishes the incentive for investment and research.

C. BACKGROUND ON BIOTECHNOLOGY

In order to better understand the controversial issues surrounding patenting of higher life forms it is best to begin with a discussion of the science of biotechnology. Biotechnology is made up of the activities of science as they are applied to living organisms. There are a number of subdisciplines that make up biotechnology. The most noteworthy of the subdisciplines, for purposes of this article, is genetic engineering.

6. Id.
7. Id.
8. Id.
9. Id.
11. NAFTA, supra note 2, at 673.
12. McMahon, supra note 10, at 34.
15. Id.
16. Id. (citing S. Chong, The Relevancy of Ethical Concerns in the Patenting of Life Forms, 10 CANADIAN INTELLECTUAL PROPERTY REPORTER 190 (1993)).
Numerous techniques are utilized in order to genetically alter animals. The methods include microinjections, cell fusion, electroporation, and retroviral transformation.17 There are many advantages to using genetic engineering instead of traditional breeding. Genetic engineering has a greater capacity to produce a specific outcome than traditional breeding.18 With genetic engineering, a specific gene can be isolated and transferred to another species. Almost any organism can donate or receive the gene, and the length of the process is reduced from generations to months.19

In recent years, the development of genetic engineering techniques has resulted in an extraordinary interest in using living organisms.20 Some examples are: human tissue and by-products, uses for new drugs, foods, chemicals, and agricultural products.21 Due to the increased interest in genetic engineering, there has been a substantial amount of money involved in this area of science.

"Within the biotechnology industry, a battle is being waged to secure the massive profits these products will potentially generate."22 However, this interest is not limited to private commerce. "Increases in government funding of genetic research have attracted intense political attention also."23

D. Transgenic Technology

The form of genetic engineering that this article will focus on is transgenic technology. Transgenic technology is now widespread in academic laboratories and biotechnology firms.24 This science involves creating plants and animals that are genetically engineered either to contain unfamiliar genes or to exclude existing ones.25

Transgenically-created animals function as living test tubes. They allow scientists to reproduce human diseases, attempt better treatments, and produce larger amounts of beneficial proteins more cheaply than ever before.26 Furthermore, transgenic animals make researching causes and possible treatments of disease easier.27

18. Id. at 151.
21. Id.
22. Id.
23. Id.
24. Id.
25. See id.
26. Supra note 20.
Scientists often use mice as living laboratories. This removes a significant amount of guesswork from the toxicological studies. In addition, transgenic animals permit the study on both the first generation animal, as well as its subsequent generations, thereby making it possible for researchers to observe the effects of the genetic mutations in the animal's offspring. In the end, the results of using transgenic animals are quicker, less expensive, and more realistic than other methods.

E. Movement to Procure Patent Protection for Living Organisms

The movement to procure patent protection for living organisms has not been easy. The progress has been met with considerable opposition. It seems as though individuals who oppose the patenting of higher life forms are those who are opposed to genetic engineering and genetic research in general.

In contrast to how opponents view patent protection for living organisms, supporters find that the object of the Patent Act is actually in accordance with their views. The purpose of the Patent Act is to encourage research and the sharing of information. It strives to achieve these goals by providing an inventor financial incentive for the efforts of his or her ingenuity, scientific know-how, and subsequent disclosure of the technology.

The opportunities that the Patent Act gives to inventors are significant. The incentives can take the form of an exclusive right to make, use, or sell a particular invention. License agreements usually provide the patent owner with some type of compensation in exchange for the licensee being free to profit from the use, manufacture, or sale of the product. The licenses can be exclusive or nonexclusive, and in addition they can cover part or all of the patent period.

F. Controversy over Patentability of Animals

The most recent controversy surrounding issues addressed in this provision is the patentability of animals. The controversy over patenting animals has been stirring since the U.S. Supreme Court's 1980 decision that allowed the patenting of microorganisms. In 1987, the Board of Patent Appeals and Interferences reversed a long-standing
Patent and Trademark Office (PTO) policy that multicellular animals did not constitute patentable subject matter.\(^9\) From this point forward, the United States has had a liberal interpretation of patentable subject matter.

In 1988, the PTO granted the first U.S. animal patent. This patent covered a genetically engineered cancer-prone mouse.\(^4\) Just four days after that decision, the Commissioner of the Patent and Trademark Office, Donald J. Quigg, announced the PTO's intention to issue patents on non-naturally occurring, non-human multi-cellular living organisms.\(^41\)

### 1. Animal Patents in the United States

#### a. The Three Patents Granted

Despite the fact that patenting higher life forms seems controversial, no clear policy has ever been articulated regarding animal patents.\(^42\) The PTO accepted transgenic animals as patentable subject matter essentially without any controversy.\(^43\) In recent years, the PTO has issued mouse patents to Ohio University, GenPharm International, and Harvard University.

The Ohio University patent (5,175,385) is for a mouse strain that continuously produces a low level of beta interferon. The significance is that beta interferon attacks viruses and helps prevent infection.\(^44\) Therefore, the purpose behind this patent is that the mouse can be used to study the immune system's response to cancer.\(^45\)

Injecting a human gene that promotes interferon secretions into mouse embryos created the strain.\(^46\) Ohio University holds the patent on this injection technique. This patent was received on December 29, 1992.\(^47\)

---

\(^9\) See id. at 195. Chakrabarty's patent claims were of three types: first, the process for the method of producing the bacteria; second, claims for an inoculum compromised of a carrier material floating on water and the new bacteria, and third, claims to the bacteria themselves. See id. at 195–96. The Court held that a live, human-made microorganism is patentable subject matter. Id. at 201.

\(^40\) See id.

\(^41\) See id. at 1026 ("[T]he PTO accepted transgenic animals as patentable subject matter, essentially, by default.").

\(^42\) Walter, supra note 27, at 1025.

\(^43\) See id. at 1026 ("[T]he PTO accepted transgenic animals as patentable subject matter, essentially, by default.").


\(^45\) Id.

\(^46\) See id.

The GenPharm mouse (5,175,384) has been engineered so that it cannot develop mature T-cells. The importance is that T-cells are vital to a functional immune system. The strain will be used in research on immune system diseases and autoimmune disorders.

GenPharm has two goals that it wishes to achieve with this patent. According to Jonathan MacQuitty, GenPharm's chief executive, the mouse mimics human immune deficiency conditions, such as AIDS. In addition, the mouse can be used to study organ transplantation.

The Harvard patent was developed in the laboratory at Harvard Medical School. The new mouse is engineered to develop benign prostatic hypertrophy, or enlargement of the prostate gland. The mouse will provide a system for testing potential drug treatments for prostate enlargement, as well as suspected carcinogens.

There has been controversy regarding the patenting of these mice. Plaintiffs in the suit filed against Patent Commissioner Donald J. Quigg argued that the office was "trying to shoehorn a conscious, sentient, thinking creature into the category 'composition of matter,'" said one of the animal rights attorneys, Steven M. Wise of Boston's Fraser and Wise P.C.

b. Controversy Over the Three Patents

As stated previously, these patents resulted in substantial debate in the United States. The greatest cause of concern seems to have been that if the PTO permits patents on animals, they may eventually allow patents on human beings also. At the government level, there were House Panel hearings and proposed moratoriums on this issue.

House Report 1556 was introduced to create awareness of the PTO's determination that genetically-altered animals are patentable. In addition, it was to clarify that human beings are not patentable, explained Representative Robert Kastenmeir (D-Wis.) in his opening statement. This concern about the issue can also be seen in the several proposed moratoriums on this issue.

House Report 1556 did not receive overwhelming support. The co-inventor of the "Harvard mouse," Dr. Philip Leder, stated that further technological advances are needed to predict or direct where a new gene will "land" among the collection of genes. In addition, Leder stated that he could not support HR 1556 because it would restrict

48. See PTO Issues Three Patents for Genetically Engineered Mice, supra note 44.
49. Id.
51. See PTO Issues Three Patents for Genetically Engineered Mice, supra note 44.
52. Id.
54. Id.
56. Id.
patent protection for the invention of any transgenic farm animal and create major
uncertainties for research and development.57

Beginning in 1987, Senator Mark Hatfield (R-Ore.) introduced legislation to place
a moratorium on animal and gene patenting. Hatfield urged that a permanent advisory
panel be set up to make policy recommendations to Congress on the social, ecological,
and ethical implications of human genetic research.58 His proposed moratorium was
only marginally effective.

Bernadine Healy, NIH Director, stated her opposition to patenting entire animals or
human beings, but pointed out that a moratorium on gene patenting would turn current
discoveries into “spent arrows” that could never be protected by patents after they are
published.59 Surprisingly, the PTO did agree to a voluntary eight-month moratorium on
animal patenting.60 Of course, following the moratorium, the PTO issued the “Harvard
mouse” patent.61

The proposed moratorium bills did not end. On September 12, 1989, Representative
Benjamin L. Cardin (D-Md.) introduced HR 3247 to impose a two-year moratorium
on the issuance of animal patents.62 Representative Cardin felt that a moratorium was
necessary to allow for the establishment of a proper regulatory review and approval
process that would take into consideration environmental, health, safety, and biomedical
ethical standards on the commercialization of an animal.63

Cardin explained that HR 3247 would provide for a moratorium on the patenting
of animal life until the proper regulatory review and approval process was in place,64 but
this proposal was not successful.

Cardin again introduced a bill, HR 4989, to impose a moratorium.65 This bill
proposed a five-year moratorium on the patenting of genetically engineered animals.66
Identical to the bill offered earlier by Senator Hatfield, the bill would have stopped
the “patenting and commercialization of genetically engineered animals pending estab-
ishment of a federal review process was to impose ‘environmental, health and safety,
economic and ethical standards.”67 This proposal also died.

c. Current State of Patentability of Animals

The current situation with patenting animals is precarious. By granting patent pro-
tection to the Harvard mouse, the PTO lifted the last obstacle in the fight for animal

57. Id.
58. See Intellectual Property: IP Laws Attempt to Adapt to Changes of New Technologies, 45 PTCJ
249 (1993).
59. Id.
60. See Legislation: House Panel Hears Testimony Addressing Animal Patenting Issues, 38 PTCJ 555
61. See id.
62. See id.
63. See id.
64. Id.
65. See PTO Issues Three Patents for Genetically Engineered Mice, supra note 44.
66. Id.
67. Id.
However, sensitivity to political pressures has affected the number of patents and the willingness of the PTO to actually grant animal patents. Furthermore, although the number of animal patents has increased, the problem remains that there are still few guidelines and many unanswered questions.

Scientists wish to patent human gene sequences and human embryos. Due to this overwhelming interest, it is important that there be a solid foundation in the law on animal patents. No court has yet to decide whether the PTO exceeded its authority by issuing its statement that they would grant animal patents.

The same criteria are required for an animal patent as for other kinds of patents. Biomedical advances that satisfy the requirements of novelty, utility, and nonobviousness may receive patent protection. Some argue that it is impossible for living matter to be novel because animals and gene sequences exist naturally.

That argument does not recognize the way biotechnology works. Biotechnology changes naturally existing organisms so that they differ dramatically from other naturally occurring organisms. In addition, the Supreme Court's decision in Chakrabarty makes apparent that non-naturally occurring organisms that have been man-made or man-altered satisfy the novelty requirement.

Proponents of the patentability of animals point out that when a transgenic animal is created, it is a product of human ingenuity. As such, it qualifies as patentable under the standard of novelty. Furthermore, by issuing it's ruling that an animal is patentable subject matter the PTO has strengthened its position stated in Chakrabarty.

2. Animal Patents in Europe
   a. Rejection of Animal Patent

The issue of patenting animals did not go without controversy in Europe either. In July 1989, European examiners rejected Harvard's application. The basis for the rejection was that the mouse was an 'animal variety,' which cannot be patented under European law.
The President and Fellows of Harvard College had applied to the European Patent Office (EPO) for a patent, and the Examining Division 023 of the EPO refused to issue a patent on the ground that the application did not meet the requirements of Articles 53(b) and 83 of the European Patent Convention (EPC). The Examining Division found Harvard’s claims unrealistically broad and not reproducible. As a result of this adverse decision, Harvard appealed.

b. Approval of Animal Patent

The “Harvard mouse” was granted patent protection in Europe in 1992. The Examining Division of the European Patent Office in Munich granted the application of the President and Fellows of Harvard College for a transgenic mouse, which will be used in cancer research. The Board of Appeal pointed out that the fact that a claim is broad is not in itself a ground for rejection. Furthermore, the Division determined that the genetic mouse is not an ‘animal variety,’ which is excluded from patentability by article 53(b) of the European Patent Convention (EPC). As such, the grant of the patent would not violate public order or morality under article 53(a).

The Division explained their rationale in the following way. Rodents or even mammals constitute a taxonomic classification unit much higher than species. An ‘animal variety’ or ‘race animal’ is ‘a subunit of a species’ and therefore of even lower ranking than a species. Accordingly, article 53(b) is not considered to cover the subject matter of the claims to animals per se.

c. Morality

Morality was a factor that the Division took into consideration. Regarding the morality question, the Division said that in the case of genetic manipulation of animals involving, as in this case, the insertion of an activated oncogene, there are compelling reasons for granting the patent. One such reason is its use in fighting cancer, which may outweigh concerns over the suffering of animals or the possible risks to the environment.

The Division also noted that it had to balance three different interests. The first interest was the “basic interest of mankind to remedy widespread and dangerous diseases.”

---

81. Id.
83. See id.
84. Genetically Engineered Mouse May Be Patentable in Europe, supra note 80.
85. Examining Division Allows Patent for Genetically-altered Mouse, supra note 82.
86. Id.
87. Id.
88. Id.
89. Id.
The second interest was the protection of the environment against "the uncontrolled dissemination of unwanted genes." And the third interest was the issue of cruelty to test animals.

d. Public Policy Considerations

The Division decided that any contribution to the development of new and improved human anti-cancer treatments "is therefore a benefit to mankind and must be regarded as valuable and highly welcome by everybody." The Division explained that current legislation in EPC Contracting States 'allows animal testing under certain restrictions and subject to administrative approval' and that this invention would require fewer test animals than conventional testing. The examining division was careful to emphasize that for each individual invention the question of morality has to be examined and possible detrimental effects and risks have to be weighed and balanced against the merits and advantages aimed at.

3. Canada's Decision to Permit an Animal Patent

Canada has been criticized for its somewhat backward attitude toward the patenting of higher life forms. Many considered the patenting of higher life forms a necessary ingredient for future progress. However, Canada currently only allows the patenting of microorganisms.

Even though microorganisms may be patented, plants, seeds, and animals may not be patented, and methods of medical treatment may not be patented. This is an administrative and judicial decision. It is important to note that this is not, or at least to this point has not been, a political decision.

In 1985, Harvard applied for a Canadian patent for the process used to develop the oncogene mouse. In 1993, the Canadian patents commissioner allowed the process, but not the animals to be patented. The Canadian practice had been to allow simple organisms, such as bacteria, to be patented, not animals.

The definitions of "invention" in the United States' legislation and in Canada's Patent Act are similar. Despite the similarities, the Board refused to give weight to U.S. practice

90. Id.
91. See supra note 82.
92. Id.
93. Id.
96. See McMahon, supra note 10, at 33.
97. See id. at 33–34.
98. Id. at 34.
100. Id.
101. Id.
in interpreting Canada’s Patent Act.102 The Commissioner refused to extend the meaning of ‘manufacture’ or ‘composition of matter’ to include a nonhuman mammal.

In addition, the Commissioner was strongly influenced by the Federal Court of Appeal decision finding that a nonhuman mammal, like a mouse, does not fall within the definition of invention in section 2 of the Patent Act.103 The Commissioner was also persuaded by the fact that the inventors could not fully control the reproducibility of the organism. In this case, the characteristics of the resulting mouse could not be controlled, since the intervention of man only ensured that reproducibility extended as far as the cancer-forming gene.104

In 1995, the trial division of the Federal Court rejected Harvard’s first appeal. The court ruled that Harvard did not ‘manufacture’ the mice because the forces of nature played a key role in developing most of the characteristics in the animal.105 However, on August 3, 2000, in a 2–1 split decision, the Federal Court of Appeal overruled that decision, saying there is nothing in the Patent Act that outlaws the patenting of animals.106

Writing for the majority, Justice Marshall Rothstein concluded that the issue is whether organisms are man-made, not whether they are living.107 He wrote that even though one could argue that natural processes determine much of the mouse’s characteristics, that interpretation would ignore the new man-made traits.108

‘The point is that control over the length of a tail, color of eyes or texture of fur is irrelevant to the usefulness of the invention,’ he wrote.109 ‘All that is important for the usefulness of the product [the use of the oncomouse in carcinogenicity studies] is that, using the methods described by the inventors, a mouse is produced with all of its cells affected by the [cancer gene].’110

In essence, the court reasoned the following: the mouse does not exist in nature, since it was only created by hard work by the U.S. researchers,111 and if the researchers are not granted a patent they won’t be able to recoup any money spent on the mouse.112

The court held that the mouse is sufficiently invention-like to be included under the general spirit of the Patent Act.113 Under the rationale of the Patent Act, as well as Judge Rothstein’s reasoning, the oncomouse is certainly the kind of useful, important, progressive step that people want to encourage to come into being.114 In an editorial

102. McMahon, supra note 10, at 34.
104. See id.
105. Clark, supra note 99.
106. Id.
107. Id.
108. See id.
109. Id.
110. Id.
112. Id.
113. Id.
114. Id.
of The Globe and Mail, the editor said, "If an anti-biotechnological interpretation of the Patent Act discourages that, we are betraying the roots of modern life." Judge Rothstein said there might be reasons why so-called 'higher life forms' should not be patented, but they have not been written into the law. Such arguments, he said, are for Parliament, and not the courts. This reasoning is like that used in the United States. However, the attempts made in the United States to suspend animal patenting have not been very effective.

The federal government is opposed to doing away with its 131-year-old Patent Act. The Federal Court of Appeal declared that there is nothing in the Patent Act of 1869 to prevent ownership rights of all animals except humans. The only requirement is that they satisfy the definition of "invention" set out in the legislation.

The judges based their decision on a strict interpretation of the Patent Act. Despite the rather fierce moral debate surrounding the issue of patenting animals, they felt that it was not their place to make a moral judgment. This court repeatedly insisted that the morality issue is a matter for Parliament, rather than the courts.

The court went on to note that section 40 of the Patent Act stipulates that the Patent Commissioner's decision on patentability is nondiscretionary. This means, an application for a patent is to be refused "where the Commissioner determines that the applicant is not, by law, entitled to be granted a patent." Furthermore, the majority noted that the issue of patentability was to be determined without regard to the conflicting policy arguments made in the case. "It is the duty of the court to take the statute as it finds it, neither expanding its interpretation beyond Parliament's intention as expressed by the language in the statute, nor limiting that interpretation by reading words of limitation into the statute not placed there by Parliament," Justice Rothstein said.

There was another interesting facet about this case—the court relied heavily on U.S. law to a greater extent than in any other important patent case. Justice Rothstein took note that the definition of "invention" in the U.S. patent statute and Canada's Patent Act are similar. As a result, he cited extensively from the leading U.S. case on the patentability of life forms, Chakrabarty. Obviously, he strongly disagreed with the Commissioner's view that U.S. case law had little weight in Canada.

The ruling has ignited a fire, calling for Ottawa to amend its legislation. People want to prevent the patenting of higher life forms and protect animal welfare, among other

115. Id.
117. Id.
119. Id.
120. Id.
122. Id.
123. Id.
125. Id.
126. Id.
things. Of course, it was not until this recent decision that people in Canada even debated the issue of patenting higher life forms.

The measure that opponents in Canada are calling for are much more grave than the proposed moratoriums in the United States in the 1980s. Opponents to the patenting of animals immediately called for the government not only to appeal, but also to consider new legislation to outlaw such patenting. "If Canada is going to make it possible to patent all life forms, if we're going to make that decision, let's make it after a broad public debate and with the proper safeguards in place," said Michelle Swenarchuk of the Canadian Environmental Law Association (CELA), which intervened in the court case.

Swenarchuk is not the only person who spoke out. Paul Muldoon of CELA stated, "There has to be a debate and there has to be legislation. What are the limits and what are the lines?" Unfortunately, for Swenarchuk and Muldoon, any decision to amend the law would ultimately rest with John Manley, the Industry Manager. A spokesman in his office said changes are not being considered.

In contrast to Europe and the United States, the "Harvard mouse" has generated relatively little public debate in Canada. The Canadian government has begun to study the issue. The Intellectual Property Policy Directorate of Industry Canada commissioned studies on the economic, ethical, and legal issues raised by patenting higher life. In addition, the Standing Committee on Environment and Sustainable Development issued a report in November 1996 on biotechnology regulation in Canada. During the pending mouse ruling, the Canadian Intellectual Property Office has about 250 applications dealing with animal patents.

The government made the decision to appeal to the Supreme Court of Canada on the last day it could, which was sixty days following the appellate court ruling. In its application, the government said it considers it necessary to refer the matter to the Supreme Court of Canada in order to obtain a definitive judgment on the scope of the current patent law. Furthermore, the government said it intends to make a motion to stay the effect of the Court of Appeal's order, pending the application to the Supreme Court.

---

127. Tibbetts, supra note 118.
128. Clark, supra note 99.
129. Id.
130. Tibbetts, supra note 118.
131. Id.
132. See Morin, supra note 17, at 148 (referring to Telephone Interview with Brian Botting, Political Analyst, Intellectual Property Policy Directorate of Industry Canada (Dec. 16, 1996)).
133. Id.
134. See Tibbetts, supra note 118.
137. Id.
4. **International Law**

On an international level, there has been a movement to harmonize and strengthen intellectual property rights worldwide. The movement has addressed the concerns of international exporters who fear piracy of their inventions, especially in less developed countries where technology receives little, if any, patent protection.\(^{138}\) It is due to this concern that the TRIPs was enacted by the signatory countries of GATT.\(^{139}\) Whereas technologically sophisticated countries are concerned about theft of technological know-how, less developed countries object to the use of their genetic resources without compensation.\(^{140}\)

G. **The "Harvard Mouse"**

Since it is specifically the "Harvard mouse" that has generated so much controversy, what exactly it is should be explained. The Harvard mouse is a genetically engineered mouse designed for cancer research. It was created through a genetic-engineering technique known as microinjection.\(^{141}\)

First, purified copies of genes are injected directly into a fertilized animal egg.\(^{142}\) The egg is then surgically implanted into the mother so that she may bring it to term.\(^{143}\) Very few of the injections result in the live birth of a transgenic animal.

Successful injections result in offspring that display traits attributable to the genes inserted in the mouse.\(^{144}\) To create the "Harvard mouse," a laboratory mouse was injected with a gene known to cause cancer. As a result, transgenic mice were extremely prone to breast cancer.\(^{145}\)

Some of the resulting mice are found to have the preferred modified genes. Then some of these mice pass them on to their offspring.\(^{146}\) These mice are referred to as "founder mice."\(^{147}\) The demand for the offspring of the founder mice in cancer research is great, and so the economic incentive to obtain patent protection is equally great.\(^{148}\)

The "Harvard mouse" serves as a valuable research tool. Since these mice are so sensitive to carcinogens, they act as detectors. Scientists can monitor both the sources of the disease and the causes.\(^{149}\)

---

138. Morin, supra note 17, at 166.
140. Id. at 167.
141. See Walter, supra note 27, at 1029.
142. Id.
143. Id.
144. Id.; see also Sellers, supra note 17.
145. Id. (citing Michael B. Landau, Multicellular Vertebræ Mammals as "Patentable Subject Matter" Under 35 U.S.C. 101: Promotion of Science and the Useful Arts or an Open Invitation for Abuse? 97 DICK. L. REV. 203, 214 (1993)).
147. Id.
148. Id.
149. See Walter, supra note 27, at 1029.
Scientists insert human genes into the mice. The human gene then mutates when it is exposed to carcinogens. "When testing a carcinogenic substance, the gene mutates indicating the carcinogenic nature of the substance." There is another useful purpose for conducting this technique on the mice. "With the mice more prone to cancers, a known time frame for developing cancer is present."

If the mouse develops cancer significantly sooner than the known time frame with the introduction of the carcinogen, the carcinogen may be implicated in the cause of human breast cancer.

Licensing rights for the patent are held by DuPont Co., which financed the Harvard research. These licensing rights could have wide commercial possibilities in cancer laboratories. And with the recent decision in Canada, it could open up a large new market for genetically-altered animals used in drug research and development.

DuPont has claimed patent protection on any anticancer product ever derived from the mice. The corporate excitement around the oncomouse reached its pinnacle in 1988, when a major financial magazine labeled the mouse the product of the year. As part of the license agreement, DuPont pays the massive legal bills that have been generated by years of litigation.

Though Harvard will not reveal the license fee paid by DuPont, it is small in corporate terms. The University takes in a total of $15 million per year from all technology licensing, a small fraction of its budget. The mice typically sell for about $50 to $60 each. Industry officials said that the impact of the ruling would not be large, since Canada is a small market. Even in the United States the demand for the oncomouse is limited.

On April 12, 1988, the PTO granted co-inventors, Philip Leder (of Harvard University) and Timothy A. Stewart (of Genentech) a patent for a genetically-altered mouse, which covers a process of injecting genes into mice embryos to make the mice susceptible to cancer, as well as the affected mice and their offspring. The mice develop tumors quickly if exposed to cancer-causing chemicals, thereby serving as a valuable

150. Id.
151. Id.
152. Id.
153. Id. (citing Gladwell, supra note 29).
157. Id.
159. Id.
160. Id.
161. Id.
162. See Morin, supra note 17, at 157 (citing to U.S. Patent No. 4,736,866; Filed 22 June, 1984; Date of Patent: 12 April, 1988).
163. See Winter, supra note 95.
'cancer detective' in testing the effects of those chemicals on humans.164 "The patent owners possess a legal right to prevent other inventors from making, using, or selling any genetically-altered mammal with human breast cancer DNA."165

In addition, the patent covers all non-human mammals created by the process.166 The patent application seeks protection for "a transgenic non-human mammal whose germ cells and somatic cells contain an activated oncogene sequence introduced into said mammal, or an ancestor of said mammal, at an embryonic stage."167 The Harvard applicants argued that, without such broad protection, someone could breach their patent by using their invention on some mammal other than a mouse.168

II. U.S. Case Law on Patentability of Living Organisms

Patenting living organisms goes as far back as 1873, when Louis Pasteur obtained a U.S. patent for yeast.169 The landmark decision on the issue that higher animal life forms are patentable is the 1980 U.S. Supreme Court case Diamond v. Chakrabarty.170 In this case, the PTO had rejected two claims for patents on unicellular microorganisms, and the case involved a genetically engineered bacterium designed to break down crude oil.171

About the same time, In re Bergy, Coats and Malik was being considered on the issue of whether an invention, otherwise patentable, is excluded from the categories of patentable subject matter because it is alive.172 The Patent Appeals Court held:

the purposes underlying the patent system require us to include microorganisms and cultures within the terms 'manufacture' and 'composition of matter' in section 101 and concluded that the fact that microorganisms are alive is a distinction without legal significance and that they should be treated under 101 no differently from chemical compounds.173

A few years later, the decision in Ex parte Allen extended patents to higher life forms.174 The patent application was for genetically modified oysters. These oysters grew bigger than natural oysters and could be harvested year-round, unlike natural oysters, which were inedible during the reproductive system.175

The "Harvard mouse" patent applies not only to the original transgenic mouse, but also to any of its progeny and any mammal bearing the inserted oncogene sequence. The

164. Genetically Engineered Mouse May Be Patentable in Europe, supra note 80.
167. Id.
168. Id.
169. See Morin, supra note 17, at 154 (referring to U.S. Patent 141, 072).
171. See id.
173. Id. at 373.
175. See Morin, supra note 17, at 156.
claims include the animals containing the oncogene because the oncogene is expressed in the phenotype of the animal. "Therefore, the unauthorized creation or use of other similarly-altered animals, such as rats or cats, would constitute infringement of the patent." 

III. Canadian Patent Protection Generally

A big issue that needs to be addressed in Canada is the scope of its Patent Act. The Canadian courts and the general public need to be aware that the Patent Act does not regulate, nor does it attempt to regulate, the subject matter it considers patentable. The object of the Patent Act is to encourage research and the sharing of information. The Patent Act attempts to do so by providing the opportunity for an inventor to gain financial reward from the efforts of his or her ingenuity, scientific know-how, and subsequent disclosure of the technology. This opportunity takes the form of exclusive right to make, use, or sell a particular invention. Essentially, the inventor is granted a limited form of property right over a particular manufacture or composition of matter.

A. Statutory Protection

The Commissioner of Patents, pursuant to the Patent Act, ultimately governs the granting of patents. The Act provides that a patent will only be granted for an "invention." Section 2 defines invention as: "any new and useful improvement in any art, process, machine, manufacture or composition of matter." 

Section 2 indicates that there are two requirements for receiving a patent. First, the item for which the patent is needed must be an "invention." Second, the invention must be both "new" and "useful."

The debate over whether the Patent Act permits patents of higher life forms is limited in scope. It is the interpretation of the general term "invention" that has given rise to the debate over whether a life form is patentable. In particular, there is considerable debate as to what constitutes a "manufacture" or a "composition of matter."

176. See id. at 157.
177. Id.
179. Id.
180. Id.
181. Id.
182. Id.
183. See id. at 15 (citing Chong, supra note 16).
185. Id.
186. Id.
B. CASE LAW ON PATENTABILITY OF ANIMALS

In Canada, the patentability of non-naturally occurring higher life forms, such as genetically-altered plants and animals, is uncertain. The central legal issue is whether such life forms come within the definition of "invention" as set forth in section 2 of the Canadian Patent Act. Unfortunately, Canadian case law is not informative as to this crucial legal issue.

Canadian patent practitioners had hoped that this issue would be resolved by the Supreme Court of Canada in Pioneer Hi-Bred Ltd. v. Commissioner of Patents, which dealt with the patentability of a new variety of soybean. However, the Supreme Court sidestepped the opportunity to squarely address this issue, and instead held the patent application invalid based on insufficient disclosure of the invention.

"Prior to Pioneer, the Patent Appeal Board had granted patents for fungi and certain living micro-organisms." In fact, some believed that this trend would be to extend to higher life forms. Despite the promising language in Re Application of Abitibi, the likelihood of higher life forms being patented was diminished by the decision in Pioneer.

As noticed with the "Harvard mouse," Canada has taken smaller steps towards the same end as the United States. In 1982, the Patent Appeal Board held that living matter could constitute a patentable subject matter. It could very well end that Canada allows patents on animals. The Patent Appeal Board noted that patent offices in the United States, Australia, the United Kingdom, Germany, and Japan have adapted their interpretation of patentable subject matter in light of current technologies and industries to grant patents for microorganisms.

"In Re Application for Patent of Pioneer Hi-Bred Ltd., the patentability of higher life forms was raised, but the Supreme Court declined to decide the issue." "Both the Patent Appeal Board and the Federal Court of Appeal narrowly construed the definition

187. Bailey, supra note 94.
188. Id.
189. Id.; see supra note 103.
190. Bailey, supra note 94.
192. See id. Ratanaseangsuang uses the example of Re Application of Abitibi, where the Patent Appeal Board suggested that it saw no reason why the patentability of living organisms should not be extended to higher life forms, such as plants and animals, provided they meet the requirements of the Patent Act. Id.
193. See id. In Pioneer, the applicant wanted to patent a new variety of soybean plant that was produced by traditional cross-breeding techniques, but still required direct human intervention, which was the breeding process. See id. Despite this element of scientific intervention, the Federal Court of Appeal rejected the soybean patent application on the ground that a plant variety produced by cross-breeding did not fall within the definition of "invention" as set out in section 2 of the Patent Act. Id.
195. Morin, supra note 17, at 163.
196. Id. (referring to Re Application for Patent of Pioneer Hi-Bred Ltd., 11 C.F.R.3d 311 (Pat. App. Bd. 1986)).
of invention, holding that a plant produced by cross-breeding could not fall within the categories ‘manufacture’ and ‘composition of matter.’ The Supreme Court of Canada unanimously disposed of the appeal solely on the grounds of inadequate disclosure.

The Canadian Manual of Patent Office Practice provides that: plants and animals are not patentable subject matter [but that] plant varieties that are distinct, uniform and stable may be protected under the Plant Breeders’ Rights Act. [Whereas] lower life forms which are new, useful and inventive are patentable...higher life forms are not patentable subject matter. However, a process for producing a higher life form may be patentable provided the process requires a significant technical intervention by man and is not essentially a natural biological process which occurs according to the laws of nature (e.g. traditional plant cross-breeding).

The decision in Pioneer represented both the first and last time that the issue of higher life form patentability came before the Canadian federal court. Although the Commissioner of Patents has referred to the case as a means by which to interpret Section 2 of the Patent Act, it is in fact, of limited guidance due to the Court’s reluctance to directly address the patentability issue.

It was not surprising that the CIPO refused the patent application for the “Harvard mouse” in Canada. The application was filed on June 21, 1985, and was rejected by the Patent Office and then by the Patent Appeals Board on August 4, 1995. The Federal Court of Canada (Trial Division) heard the appeal brought by the President and Fellows of Harvard College on November 17, 1997. A. David Morrow, the Ottawa attorney who argued the case for Harvard, predicts that the case will be heard in the Court’s 2001 session.

IV. Canada’s Approach Becoming More Like the United States

The Canadian approach to the patentability of higher life forms stands in direct contrast to that of the United States, which has been calling for the patenting of “everything under the sun made by man.” Despite the Canadian courts’ often reluctance to use U.S. precedent when interpreting Canadian statutes, in this specific instance there is a close factual tie between the two jurisdictions that renders the U.S. jurisprudence particularly relevant. The Canadian courts may not want to acknowledge the marked similarity between the Canadian and U.S. statutes, but the fact remains that the two jurisdictions are quite comparable.

197. See Morin, supra note 17, at 164.
198. Id. (referring to Pioneer Hi-Bred Ltd. v. Commissioner of Patents, 25 C.P.R.3d 257, 265 (S.C.C. 1989)).
200. Ratanaseangsuang, supra note 14, at 17.
201. Id.
202. See Morin, supra note 17, at 165.
203. Id.
204. See id. at 166.
205. Gewolb, supra note 158.
206. Ratanaseangsuang, supra note 14, at 19.
Section 2 of the Canadian Patent Act is parallel to 35 U.S.C. 101. That provision aims to protect "anyone who invents or discovers, a process, machine, manufacture, composition of matter, or improvement thereof." In addition, it is a well-known fact that "the statutory provisions of Canadian law have borrowed extensively from the U.S. system."

Many Canadian patents are issued for foreign technology that is developed in the United States. The fact that biotechnology is moving towards a trend of international globalization constitutes a reason why the Canadian court may have looked beyond the Canadian jurisprudence and patenting tradition when it decided the issue of patenting higher life forms. Despite these legitimate reasons, this recent decision has not gone without controversy.

David Conn, patent agent with an Ottawa law firm, told BioWorld Today that the decision is surprising in view of the Patent Office's longtime refusal of claims to higher life forms and the federal court's reluctance to tackle politically-charged issues such as this one. He also noted that it should provide an additional incentive for biotechnological research and development to be carried out in Canada. Also, according to Joyce Groote, President of BIOTECanada, this decision means that innovators of new, multicell plant and animal products obtained using biotechnology now have patent protection for their innovations.

Many feel that Canada's biotechnology is in danger of losing ground. Some people feel that Canada is losing ground because of Ottawa's reluctance to confront the controversial issue of animal patenting. Dr. Jack Wearing, chairman of the Industrial Biotechnology Association of Canada, said that the decision to deny a patent in Canada to Harvard University for a genetically engineered mouse was "a setback for the advance of the biotechnology sector."

In addition, Wearing also noted that this is the sort of issue that countries that want to lead in biotechnology need to address. The United States, Europe, Japan, Australia, and France have all made positive decisions in the area of animal patents.

207. Id. at 19-20.
208. Id. (citing I. Goldsmith, Patents of Invention (Toronto: Carswell, 1981)).
209. Id.
210. Id.
211. See Stephanie Boyd, Campus Mice Scampering North Work for DuPont, Toronto Star, Aug. 18, 2000 ("Rather than helping find a cure for cancer, the new Canadian patent will increase research costs since buyers and breeders of the mouse will have to pay royalties to DuPont.").
212. Winter, supra note 95.
213. Id.
214. Id.
216. Id.
217. Id.
218. Id.
“Unfortunately, the Canadian approach has been to commission endless studies to, in effect, postpone addressing the issue,” stated Wearing.  
Opponents to the patentability of higher life forms suggest that it won’t end with mice. Pat Mooney, executive director of the Ottawa-based Rural Advancement Foundation International, said, “It’s not just a mouse, of course. It’s a mammal. And if the patent is granted on this mouse just for experimental purposes, then it could be granted on cows, chickens, pigs or us.” “It would be hard for the Canadian government to stop any of that once this patent was granted.”

The court rulings on this matter have twice agreed that the issue of life patenting is more appropriately decided by Parliament. Curiously, the government continues to avoid the democratic process. Many see this inaction as hiding beneath the judge’s robes. Through other official documents, such as the Canadian Biotechnology Strategy, the present government has made it clear that they support the biotechnology industry’s desire for patenting anything that moves.

V. Canada’s Reaction to the Federal Appeals Court Decision

The federal appeals court announcement marks the first time that patent law will protect a genetic change in a higher life form. Not everyone is happy about this latest decision. “We’re outraged,” said Jeremy Rifkin, president of the Foundation on Economic Trends, an anti-biotechnology group based in Washington.

On the other hand, some see this latest decision as no great surprise. Geoffrey Karny, a Washington patent attorney, felt that this was “not a radical departure from existing policy. Granting a patent on animals is an entirely logical application of existing patent law principles, and in many respects is nothing different from what society has been doing with regard to the commercial ownership of animals for thousands of years.”

Industry experts said that with the guarantee of patent protection for the fruits of research and development, the number of companies doing research could increase. In addition, the amount of money spent on its research and development could skyrocket in the next few years. The result could be dramatically lower costs for producing drugs.

“Patent protection is the lifeblood of the pharmaceutical and biotechnology industries,” said Steven Holtzman, chief operating officer of the Ohio-based Embryogen Corp., one of a handful of companies nationwide that have been developing genetically-altered

219. Id.
221. Id.
222. RAFF, supra note 156.
223. Id.
225. Id.
226. Id.
227. Gladwell, supra note 155.
228. Id.
animals for laboratory and commercial use. Don Hudson, president of the Worcester, Massachusetts-based Transgenic Sciences Inc., said, "[t]his patent decision gives everyone much more incentive to enter this field." Companies involved in "transgenic" animals say patent protection is crucial, because otherwise they have no way to prevent customers from simply buying one animal and breeding as many others as they like.

Some have noted that the court ruling could help Ottawa's biotech sector attract venture capital. The ruling makes it more commercially practical for Canadian biotech firms, including those in Ottawa's own growing industry, to develop groundbreaking advancements. Many biotech firms just need capital from companies in order to put their ideas into use.

"It will make it easier to get commercial interest and attract venture capital here," said Peter Morand, chair of the Ottawa Life Sciences Council. That's because investors prefer to sink money into companies whose innovations are patented. "Canada is lagging behind in its acceptance of allowing these patents," Morand said. "This (ruling) puts Canada on a more even playing field in terms of commercializing these technologies."

While many are excited at the prospects for the future, some are a little more cautious in what this ruling really means. Joyce Groote, president of Ottawa-based industry group BIOTECAnada, said, "You must still go through an extensive regulatory approval process that is also subject to research ethical boards. This judgment does not change one iota of that."

Lobbyists for the biotechnology industry argue that Canada should get on board. What some find most worrisome about all of this is that there has been virtually no public discussion in Canada about either the risks or ethics of genetic engineering. The federal government has so far chosen to duck all of the hard questions.

In 1996, a Commons committee called on the government to implement new legislation and regulations to control genetic engineering. The government has not done

229. Id.
230. Id.
233. Id.
234. Id.
235. Id.
236. Id.
237. Id.
238. Wong, supra note 232.
240. Id.
241. Id.
242. Id.
so. Instead, the government appears content to take its lead from industry, market forces, and the courts.

The Canadian Environmental Law Association (CELA) complains that even in the 'Harvard mouse' case the Canadian government is arguing its case too narrowly. In private, government officials agree that is exactly what they are doing. A lawyer who works for the biotechnology industry said, "If the court says that, yes, animals are patentable, then the government might well change its patent policy." Regardless of how good the fruits of this decision may seem to many, there are many other people who do not see this decision as a good outcome. Critics claim that the ruling commercializes the blueprint for life itself. "This is saying that if you tweak one mammal in a certain way, you can own the patent to the whole mammal," said Paul Muldoon of the CELA. Muldoon called the decision "the commodification of life."

Richard Gold, a law professor at the University of Western Ontario, said Canada probably should not refuse to grant such patents since many of its biggest trading partners already do. But, said Gold, "subjecting higher life forms to the same type of patent protection as you give to the mouse trap or a light bulb or a chemical is probably not completely appropriate either." Gold believes the government needs something in between.

VI. Policy Reasons for the Uses of Transgenic Animals

A. Reasons Against Patentability of Transgenic Animals

Developing countries are not importers of technologies and patented products and for the most part are opposed to the patenting of life. Many of them have been following the 'Harvard mouse' case in Canada, hoping it would strengthen their opposition to the life patenting provisions of the TRIPs agreement.

Another strong argument against patenting animals is concern over cruelty to animals. Opponents say that the availability of patent protection for these new animals will lead to an increase in the number of animals born with crippling and painful defects. Opponents argue that as a result, "new forms of cruelty" to animals will ensue.

Meanwhile, proponents of transgenic animal uses say that "a lawsuit of this kind does not serve any kind of public interest," said George A. Frank, a senior attorney for

243. Id.
244. Walkom, supra note 239.
245. Id.
246. Id.
247. Id.
249. Id.
250. Id.
251. Id.
252. Id.
253. Id.
254. RAFI, supra note 156.
255. Id.
256. Lavelle, supra note 53 (referring to Quigg, supra note 72).
the medical products department of I. E. DuPont De Nemours & Co. Others also said that the patent system is a "morally and politically neutral" system for judging whether an individual is entitled to a property right for his or her invention.

Opponents also point out that many of these transgenic animals are used for profit. Ursula Franklin, an experimental physicist and professor emeritus at the University of Toronto, sees "science moving away from the common good, toward profit...with patenting being one of the means to that profit." "When Canadian researchers Frederick Banting and Charles Best discovered insulin in 1922, they decided not to take out a patent and profit themselves, but scientists are now and tend to view their findings as private property," says Franklin. In many disciplines, this is acceptable, says Franklin, but in biotechnology, the issues can often deal with fundamental questions about the essence of life itself.

Others disagree with the patenting of animals because they feel that it is actually counter-productive. Some groups believe that in some situations, proliferating patents can actually inhibit the progress of research. The argument is that they give patent holders a license to charge whatever the market will bear from the resulting products.

There is also concern that this type of holding is not advantageous to all countries. Developing countries may have little to gain, and much to lose, from a system of intellectual property protection that is organized around the priorities of large corporations. Further complications arise because commitments under NAFTA and the WTO create obstacles for any country that wishes to craft a distinctive approach that balances commercial and other imperatives.

B. REASONS FOR PATENTABILITY OF TRANSGENIC ANIMALS

There is always the concern for investment and development. Opponents argue that the biotechnology industry is lobbying the Canadian government to follow the lead of the European Union, Japan, Australia, and other countries that allow patenting of higher life. However, proponents say that patent rights are critical if Canadian biotechnology companies are to "attract and hold the investment necessary to develop their inventions in Canada."

Some authors have taken notice that transgenic animals and human gene sequences have enormous commercial value in agriculture, biomedical research, medicine, and

257. Id.
258. Id. (statement made by biotechnology lawyer Geoffrey M. Karney of Dickstein, Shapiro & Morin).
260. Id.
261. Id.
263. Id.
264. Id.
265. Orwen, supra note 259.
266. Id.
the pharmaceutical industry.\textsuperscript{267} Furthermore, transgenic animals, or genetically-altered animals, can serve as models to study human diseases and test drugs. Also, they are being developed to donate organs for transplantation in humans.\textsuperscript{268}

In addition to the social reasons, a number of commentators have noted that there are economic incentives resulting from animal patenting.\textsuperscript{269} The most dramatic evidence of the economic incentive resulting from animal patenting has been the significant increase in the stock values of corporations engaged in biotechnology research.\textsuperscript{270} There are many examples of companies that have gained significant amounts of money from being involved in the biotech industry.

Just four months after the U.S. Supreme Court decision in \textit{Chakrabarty}, Genentech raised $36 billion in one day by its public stock offering.\textsuperscript{271} A 1984 National Academy of Sciences study estimated that the biotechnology industry could yield a yearly business of between $40 billion and $100 billion.\textsuperscript{272} With evidence like this, there is no doubt that patents stimulate the growth of industry and, therefore, the industry of biotechnology welcomes any patent protection it receives.\textsuperscript{273}

Jason Flint, general manager of the Industrial Biotechnology Association of Canada, estimates that the core industry is capitalized at about one billion dollars already and is growing by about 26 percent a year.\textsuperscript{274} As well, most of the powerful multinational drug firms, with all their political clout, are involved.\textsuperscript{275} In addition, governments are anxious for any good news on the job front, which regularly laud biotechnology as the wave of the future.\textsuperscript{276}

Various people have noted that it is one of the two technologies in America that will define the next century's economic progress and the well being of society.\textsuperscript{277} The field encompasses the whole range of life sciences.\textsuperscript{278}

There is further evidence that the biotechnology industry has had positive effects on the economy. "Having barely existed a generation ago, the biotechnology industry in recent years has mushroomed, roughly doubling in size between 1993 and 1999,

\begin{thebibliography}{99}
\bibitem{267} Walter, \textit{supra} note 27, at 1029 (citing Jones, \textit{supra} note 72, at 880–81).
\bibitem{268} See Morin, \textit{supra} note 17, at 148.
\bibitem{269} See Sellers, \textit{supra} note 17, at 284.
\bibitem{270} Id.
\bibitem{271} Id. (citing Jeremy Rifkin, \textit{Algeny} 7, at 11 (Viking Press 1983)).
\bibitem{272} Id. (citing \textit{Coordinated Framework for Regulation of Biotechnology: Hearing Before the Subcommittee on Investigations and Oversight and the Subcommittee on Natural Resources, Agriculture Research and Environment and the Subcommittee on Science, Research and Technology of the House Committee on Science and Technology, 99th Cong., 2nd Sess. 6 (1986))
\bibitem{273} See Walter, \textit{supra} note 27, at 1025.
\bibitem{274} Walkom, \textit{supra} note 239, at A2.
\bibitem{275} Id.
\bibitem{276} Id.
\bibitem{277} Julius A. Karash, \textit{KC Seeks to Fly Banner in Biotech Revolution; Explosion of Biological Science Kindles Hope for New Cures, Forges Dreams for Area Economy}, KAN. CITY STAR, Oct. 15, 2000, at A1 (statement was made by Richard J. Mahoney, former head of Monsanto Co. and now an executive in residence at the Center for the Study of American Business at Washington University in St. Louis).
\bibitem{278} Id.
\end{thebibliography}
to employ more than 153,000 people in high-wage jobs.” 279 “More than 1,200 biotech companies now operate in the United States.” 280

It is an expensive business. 281 Flint notes that biotechnology firms want to market their products worldwide to spread the costs of research. 282 More particularly, they want worldwide monopolies on the genetically-altered plants or animals they create. 283

An animal with cancer genes would allow for more sophisticated and effective testing of carcinogens. Moreover, it could prove to be useful in testing potential drug therapies. This permits scientists to study breast cancer in a living system and test drugs without involving human patients. 284

“To a young growing company, intellectual property is essential for attracting and maintaining investments through the years it takes to develop important, innovative products, products that benefit consumers.” 285 Patents also make knowledge publicly available. 286 This new information becomes accessible to the scientific community and stimulates further innovation. 287

The fact that the Patent Office refuses applications made upon a particular subject matter simply means that subject matter is unregulated by patent legislation. 288 It does not amount to a prohibition upon the use of that technology, nor does it mean that there will be a reduction in the use of products that utilize that technology. 289 The current practice of refusing to patent higher life forms merely encourages companies to conduct research of this type outside Canada, the products of which are not prevented from being used in Canadian industry. 290 Further, it forces researchers to seek other methods, such as keeping the information secret, in order to protect their inventions. 291 Arguably, a situation where genetic research activities go undisclosed is not a desirable one for the overall good of society. 292

While it is possible that revising current policy in order to allow the patenting of higher life forms might conceivably encourage more research in this area (which is the objective of the Patent Act), it does not follow that it will then become more difficult to regulate genetic engineering practices. 293 In fact, by allowing a more liberal interpretation of section 2, the courts arguably make room for Parliament to enact specific legislation

279. Id.
280. Id.
281. Walkom, supra note 239.
282. Id.
283. Id.
284. Gladwell, supra note 155.
286. Id.
287. Id.
289. Id.
290. Id.
291. Id.
292. Id.
293. Id.
regulating the fruits of biotechnology. This is the more appropriate and measured approach to take if they are to achieve a satisfactory resolution to the issue of genetic engineering.

A 1994 survey indicates that about 60 percent of Canadians were undecided in their attitudes toward genetic engineering, while an almost equal percentage of Canadians described themselves as true believers and avid opponents of the technology. Thus, a greater awareness of the nature of genetic engineering is needed in order to raise consumer confidence in the field. In addition, the development of the laws relating specifically to biotechnology would help fill the gaps in legislation that arise as science outpaces the law. However, the law will not be able to respond immediately to every new development as it arises, and the laws will not necessarily prevent the unethical uses of genetic engineering.

C. INTERNATIONAL CONSIDERATIONS

Even if a country tried to resist the trend towards patenting higher forms of life, it would confront two realities. First, the biotech industry is international. Companies can easily move from one country to another in order to take advantage of favorable regulatory climates. Therefore, efforts by any one country to aggressively enforce ethical standards may well encourage companies to move elsewhere.

Second, regulating countries face a set of international conventions relating to patents and international trade. A country wanting to exclude animal patents would be subject to trade sanctions under the World Trade Organization agreements unless it could prove that the sale of that material would violate moral standards.

VII. Conclusion

This article set out to determine whether the latest Canadian decision in the “Harvard mouse” case has essentially made the intellectual property provision in NAFTA superfluous. There does not seem to be a clear answer. What is clear is that Canada, and
the United States for that matter, needs to articulate a clear policy on the patentability of higher life forms.

The ability to patent animals allows many good outcomes to having the ability to patent animals. Scientists can find cures for diseases. In addition, the field of biotechnology creates many jobs and helps the economy in numerous ways. However, the ability to patent animals can also present a dark side.

Neither the court systems in the United States nor Canada have addressed this specific issue. However, it appears that in both jurisdictions the courts want to interpret the patent statutes in such a way as to permit the patenting of animals. The statutes the courts use for guidance do not expressly prohibit this act.

Both countries have essentially determined that the patentability of animals falls under the definitions in their respective statutes. What both jurisdictions seem to be looking for is guidance from the government. In the United States, there were several proposed moratoriums, and only one was even minimally successful. Canada has not taken any such action.

We live in an ever-changing world and it seems that the only proper solution is to draw a compromise. Both governments probably would agree that there are many far-reaching benefits to patenting animals. However, both governments would also probably acknowledge a great potential for disaster if there were not proper regulations and guidelines by which the biotech industry must abide.

It is important for there to be clear guidelines in this area, as to avoid animal cruelty, not exploit underdeveloped nations, and not implicate what seems to be the inevitable—patenting humans. These concerns can be balanced against the desire to learn more about diseases, create more jobs, and boost the economy. However, it will be up to the governments to take action, since that is simply beyond the function of the courts.

Furthermore, if the governments do choose to take affirmative steps to regulate patents on higher life forms, it would create greater awareness about the biotechnology field. So many people do not understand genetic engineering and transgenic animals. Government regulations would be beneficial to everyone, because maybe some people that have traditionally opposed biotechnology might then attain a better understanding of the field.

In the end, I believe that as the years go by, the current state of the intellectual property provision of NAFTA regarding the patentability of plants and animals will be superfluous, if it is not already. In an age where the biotech industry is booming and employing numerous people, and scientists are able to discover cures for what once were considered incurable diseases, it is difficult to imagine that Canada will choose not to be a part of that market.
Law and Business Review of the Americas

— Board of Professional Editors —

Hon. EIC: Professor Roberto MacLean
President, SMU - LIA

Editor-in-Chief
Joseph J. Norton
SMU-Dallas/CCLS-London

Deputy Editor-in-Chief
Lawrence B. Pascal
SMU-Dallas

Deputy Editor-in-Chief
Jorge M. Guira
London-Warwick

Deputy Editor-in-Chief
Diego C. Bunge
Buenos Aires/SMU-Dallas

David W. Banowsky
Dallas

Mauricio Bacquero
CCLS-London

Thomas W. Slover
Dallas

Emily S. Barbour
Dallas

Jill A. Kotvis
Dallas

Roland P. Wiederaenders
Austin

Jorge A. Gonzalez
Dallas

Rosario Segovia-Heppe
Dallas

— 2001-2002 International Law Review Association Faculty Advisory Board (SMU) —

George A. Martinez, Chair

Christopher H. Hanna
John S. Lowe
Daniel J. Slottjie (Econ.)

Susan Scafidi
Marc I. Steinberg
L. Mike Wooten (Bus.)

Jane Kaufman Winn
Peter Winship
Michael Lusztig (Pol. Sci.)
— Advisory Board —

— ABA Representatives —

Chair: Lucinda Lowe  
Washington, D.C.

Juan F. Torres-Landa  
Mexican Law Committee

James A. Silkenat  
L.A. Law Initiative

Jose A. Santos, Jr.  
Inter-American Committee, Miami

Dean Saul  
Canadian Committee, Ottawa

John R. Magnus  
International Trade Committee

— External Representatives —

Mr. Lee Bucheit  
New York

Sergio Leiseca  
Dallas

Kevin Banks  
Washington, D.C.

Prof. Em. Beverly Mae Carl  
Santa Fe

Rona R. Mears  
Dallas

Dr. Alejandro M. Garro  
New York/Dallas

Prof. Marsha C. Echols  
Washington, D.C.

Prof. Frank J. Garcia  
Tallahassee

Hon. Miguel Otero  
Santiago

Prof. Michael W. Gordon  
Gainesville

Tom J. Farer  
Denver

Dr. Rosa Lastra  
London

Dr. Hector Mairal  
Buenos Aires

Prof. Leon Trakman  
Nova Scotia

Prof. Donald Buckingham  
Saskatchewan

Prof. Benjamin Geva  
Toronto

Dr. Eva Holz  
Montevideo

Dr. Ernesto Aguirre  
Washington, D.C.

Dr. William C. Gruben  
Dallas

Dr. Leoncio Lara  
Mexico City

Louis Capin L  
Mexico City

Dr. William Johnson  
Dallas

Julio Cueto-Rua  
Buenos Aires

Cynthia C. Lichtenstein  
Boston

David J. McFadden, Q.C.  
Toronto

Boris Kozolchyk  
Tucson

Stephen T. Zamora  
Houston

Joel P. Trachtman  
Boston

Dana G. Nahlen  
Plano

OFFICIAL CITATION


Nothing herein shall be construed as representing the opinions, views or actions of the American Bar Association unless the same shall have been first approved by the House of Delegates or the Board of Governors, or of the Section of International Law and Practice of the Association unless first approved by the Section or its Council.
Established in 1952, the Law Institute of the Americas at Southern Methodist University Dedman School of Law was originally designed to promote good will and to improve relations among the peoples of the Americas through the study of comparative laws, institutions and governments respecting the American Republics, and to train lawyers in handling legal matters pertaining to the nations of the Western Hemisphere. Today, in reviving this institution, the Law Institute of the Americas comprises meaningful academic research, teaching and programs pertaining to the "NAFTA/FTAA processes" and other Western Hemispheric integration efforts; to Latin and Central American law and judicial reform, particularly focusing on Argentina, Brazil, Chile, Guatemala, Mexico, Peru and Venezuela; and, to a more limited extent, to Canadian legal issues, particularly as they interrelate to the NAFTA/FTAA. The Law Institute of the Americas also is concerned with increasing (regional and hemispheric) legal and economic interconnections between the "NAFTA/FTAA processes" and European and Asia-Pacific integration activities.

The officers of the Institute are as follows: the Honorable Roberto MacLean, President; Professor Joseph J. Norton, Executive Director; and Professor George A. Martinez, Associate Executive Director. Professor Julio C. Cueto-Rua of Argentina, and one of the first SMU international LL.M. (then MCL) graduates, serves as Honorary President of the Institute. The Institute is also supported by a distinguished group of Professorial Fellows, Senior Research Scholars, Professional Fellows, and Student Research Fellows. Corporate sponsorship of the Institute has been provided by H.D. Vest Financial Services.

As the Institute focuses primarily on issues pertaining to the North American Free Trade Agreement and the pending Free Trade Area of the Americas, and the broader economic, political, legal and social integration processes underway in the Western Hemisphere, Law and Business Review of the Americas is one of its publications, and is produced jointly by the Law Institute of the Americas and the International Law Review Association of SMU. Other parties involved in the production of the journal are the SMU School of Business, the SMU Departments of Economics and Political Science, the University of London, Centre for Commercial Law Studies, the American Bar Association Section of International Law and Practice and Kluwer Law International.

* From 1952 through the early 1970s, the name was the Law Institute of the Americas; in 1993, it was reactivated as the Centre for NAFTA and Latin American Legal Studies; and in 1998, it returned to its original name. For further detailed historical information on the Law Institute of the Americas, please refer to the LIA's Web site, http://www.law.smu.edu/lia.